Group 1 - Core viewpoint: Furuya Medical Technology (01696) saw a stock increase of over 6%, currently trading at 5.98 HKD with a transaction volume of 10.9752 million HKD [1] - Furuya Medical Technology announced a commercial distribution cooperation agreement with Fosun Wanbang, which will provide services for the product Botulinum Toxin Type A, branded as Daxife in mainland China [1] - The annual transaction cap for this agreement is set at 17 million USD for the period from yesterday until the end of this year and the next year [1] Group 2 - The product is intended for the temporary improvement of moderate to severe frown lines caused by the activity of the glabellar muscles in adults [1] - The agreement is expected to generate additional revenue for the company [1]

Core Viewpoint - Furuya Medical Technology (01696) has seen a stock price increase of over 6%, currently trading at 5.98 HKD with a transaction volume of 10.9752 million HKD, following the announcement of a commercial distribution cooperation agreement with Fosun Wanbang [1] Group 1: Company Developments - Furuya Medical Technology has entered into a commercial distribution cooperation agreement with Fosun Wanbang, which will provide services for the product Botulinum Toxin Type A, marketed as Daxifei in mainland China [1] - The agreement includes commercialization, marketing, medical education, and business planning services, with an annual transaction cap of 17 million USD for this year and the next [1] - The product is designed to temporarily improve moderate to severe frown lines caused by the activity of the glabellar and/or corrugator muscles in adults [1]